BridgeMD
New treatment option for Localized Prostate Cancer
Official title Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
ClinicalTrials.gov ID: NCT06325774
What this study is testing
- What it's testing
- The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer. Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Age: ≥18 years old;
- European Cooperative Oncology Group score(ECOG):≤ 2;
- Patients with pathologically diagnosed prostate cancer;
- Clinical stage was cTanyN0M0 any Gleason / ISUP group;
- Expected survival time \>5 years;
You likely can't join if
- Patients who have received any other early treatment for prostate cancer, including radiotherapy, chemotherapy, focal therapy, etc;
- a previous history of pelvic and abdominal radiotherapy;
- Prior hormonal therapy (castration or antiandrogen);
- Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or...
- Patients that the investigator considers unsuitable to participate in the clinical trial; patients with other serious systemic diseases, evaluation...
- Patients with contraindications related to radiotherapy;
See the full eligibility criteria
- Age: ≥18 years old;
- European Cooperative Oncology Group score(ECOG):≤ 2;
- Patients with pathologically diagnosed prostate cancer;
- Clinical stage was cTanyN0M0 any Gleason / ISUP group;
- Expected survival time \>5 years;
- The patient has no contraindications to radiotherapy and is suitable and willing to undergo radiotherapy;
- Patients who voluntarily accept the experimental study protocol after being informed about the existing treatment options;
- Patients who have received any other early treatment for prostate cancer, including radiotherapy, chemotherapy, focal therapy, etc;
- a previous history of pelvic and abdominal radiotherapy;
- Prior hormonal therapy (castration or antiandrogen);
- Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis;
- Patients that the investigator considers unsuitable to participate in the clinical trial; patients with other serious systemic diseases, evaluation and compliance of the trial, including severe respiratory, circulatory...
- Patients with contraindications related to radiotherapy;
- Participate in other clinical trials that are mutually exclusive with the study intervention within 4 weeks prior to the start of the study;
- Patients unable to provide written informed consent or demonstrate poor treatment compliance
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.